Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 181,998 shares of the biopharmaceutical company’s stock after buying an additional 15,997 shares during the period. Pfizer comprises 0.7% of Bronfman E.L. Rothschild L.P.’s holdings, making the stock its 25th largest position. Bronfman E.L. Rothschild L.P.’s holdings in Pfizer were worth $6,497,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. Norinchukin Bank The lifted its stake in Pfizer by 3.2% in the 3rd quarter. Norinchukin Bank The now owns 782,374 shares of the biopharmaceutical company’s stock valued at $27,931,000 after purchasing an additional 24,619 shares during the last quarter. ING Groep NV lifted its stake in Pfizer by 122.9% in the 3rd quarter. ING Groep NV now owns 2,061,747 shares of the biopharmaceutical company’s stock valued at $73,604,000 after purchasing an additional 1,136,670 shares during the last quarter. D.A. Davidson & CO. lifted its stake in Pfizer by 1.6% in the 3rd quarter. D.A. Davidson & CO. now owns 388,242 shares of the biopharmaceutical company’s stock valued at $13,860,000 after purchasing an additional 6,084 shares during the last quarter. Pinnacle Financial Partners Inc. lifted its stake in Pfizer by 9.8% in the 3rd quarter. Pinnacle Financial Partners Inc. now owns 132,419 shares of the biopharmaceutical company’s stock valued at $4,728,000 after purchasing an additional 11,768 shares during the last quarter. Finally, Sound Shore Management Inc. CT lifted its stake in Pfizer by 12.3% in the 3rd quarter. Sound Shore Management Inc. CT now owns 5,338,219 shares of the biopharmaceutical company’s stock valued at $190,574,000 after purchasing an additional 584,198 shares during the last quarter. Institutional investors own 69.87% of the company’s stock.
In other news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.
Shares of Pfizer Inc. (NYSE PFE) opened at $35.28 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The stock has a market cap of $210,290.00, a P/E ratio of 10.02, a price-to-earnings-growth ratio of 2.20 and a beta of 0.94. Pfizer Inc. has a 1 year low of $31.67 and a 1 year high of $39.43.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The business’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the business posted $0.47 earnings per share. sell-side analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.
Pfizer declared that its Board of Directors has approved a stock buyback program on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.85%. Pfizer’s dividend payout ratio (DPR) is 38.64%.
TRADEMARK VIOLATION NOTICE: “Bronfman E.L. Rothschild L.P. Acquires 15,997 Shares of Pfizer Inc. (PFE)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.com-unik.info/2018/02/07/bronfman-e-l-rothschild-l-p-acquires-15997-shares-of-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.